Tumors of the brain and central nervous system can be fatal, and surgery is often required for their removal. To avoid disease recurrence, it is necessary to ensure that the tumor is completely removed. “While removing the tumor, a clinician often needs to look for any leftover tumor tissue,” Dr. Borah explained.
Analysis of frozen biopsies is the gold standard for rapid tumor evaluation, including intraoperative tumor assessment. However, frozen biopsy is labor-intensive and time-consuming, as it requires physical sectioning of frozen tissue samples, staining with H&E, and manual tissue evaluation under a microscope. This may prolong the surgery time and limit the number of intraoperative assessments that can be safely performed.
“To address limitations of intraoperative tumor assessment using frozen biopsies, we sought out to develop an alternative intraoperative tissue assessment method that is fast, accurate, artifact-free, and readily deployable without machine learning and additional interpretation training to the pathologists,” Dr. Borah noted.
To address the limitations of intraoperative tumor assessment using conventional frozen sections, the team developed a training-free H&E-based digital pathology method for rapid evaluation of fresh brain tissues, which they termed “Rapid Fresh digital Pathology” or simply “RFP”.1 RFP is a whole-specimen superficial-imaging (WSSI) method that provides traditional H&E-specific histopathological features without the need for physical sectioning.
“When we talk about rapid assessment, an important aspect is the imaging speed. Certain specimens can be as large as a square centimeter or even more. Therefore, scanning and visualization must be completed within a few tens of seconds. While doing so, maintaining a high digital resolution is imperative for a reliable assessment,” Dr. Borah explained.
To achieve rapid imaging while maintaining a high image resolution, the team developed a mesoscale Nonlinear Optical Gigascope (mNLOG) platform with a streamlined rapid artifact-compensated 2D large-field mosaic stitching (rac2D-LMS) approach,1 allowing laser-scanned gigapixel imaging with real-time mosaic stitching.
This pipeline entails H&E staining of fresh human brain specimens using a rapid whole-mount soft-tissue staining protocol, which takes less than 6 minutes and enhances nuclei contrast. After staining, the samples are analyzed using the mNLOG platform, which combines nonlinear multiphoton imaging (two-photon excitation fluorescence) and multi-harmonic generation imaging (third harmonic generation) techniques to yield histopathological images of the H&E-stained tissues.
The researchers evaluated the feasibility and performance of the RFP technique using fresh human brain specimens obtained during surgery. This method allowed them to optically section fresh brain specimens and generate high-resolution 2D digital images of a 1 cm2 area in less than 120 seconds.1 The fact that this rapid digital pathology workflow significantly reduces the turnaround time for diagnostic evaluations compared to frozen biopsy methods could have significant implications for clinical decision-making, especially in time-sensitive cases, such as intraoperative consultations.
“In the domain of digital surgical pathology, our laser scanning platform, for the first time, provides a whole-specimen superficial-imaging solution maintaining the state-of-the-art whole-slide imaging (WSI) standard, while enabling post-processing-free centimeter-scale multicolor imaging at submicron digital resolution.” Dr. Borah explained.
The digital images of a 1 cm2 area could reach 3.6 gigapixels, and scanning was achieved at a sustained effective throughput of >700M bits/sec, with no post-acquisition image processing. The method provided excellent image fidelity, enabling pathologists to assess cellular details and tissue architecture with high accuracy.1
RFP and formalin-fixed paraffin-embedded (FFPE) biopsy datasets consisting of 50 normal and tumor brain specimens from eight individuals were assigned to two sets of independently generated random IDs and sent to two pathologists for evaluation. This analysis showed 100% concordance in the outcomes between FFPE biopsy and training-free blind tests using the RFP technique. These findings suggest that RFP provides excellent sensitivity and specificity, comparable to FFPE biopsy, which is the current gold standard method.
“Being based on H&E staining, our approach does not require machine learning or additional interpretation training for the pathologist, and the approach can readily be extended to other organ specimens,” said Dr. Borah.
Furthermore, the digital pathology approach eliminated the need for specialized infrastructure and storage facilities for frozen sections. This could potentially lower costs, improve resource utilization, and streamline laboratory operations in pathology departments.
Despite the promising performance of this new digital pathology method, the pipeline was tested only on fresh brain specimens. Future studies are needed to test the feasibility of this method for the rapid evaluation of other types of fresh specimens, such as liver, lung, breast, and skin.
Commenting on their future work, Dr. Borah noted, “We will conduct more clinical studies to assess the performance of our proposed method for different types of specimens.”
In addition, the team is working on setting up a startup called mesoView Co. Ltd. with an aim to develop PATHOscope, a stand-alone movable device, to accelerate and broaden the research on rapid fresh digital pathology.
Back to listing亞洲指標新創展會 InnoVEX 主辦單位之一台北市電腦公會(TCA)表示,綠色科技永續營運是全球趨勢,Research and Markets研究報告指出,綠色科技和可持續性發展需求快速增加,預估全球市場將從2024年的286億美元,成長至2030年的1,349億美元,年複合成長率(CAGR)高達29.5%,因為全球企業正在透過採納綠色技術和可持續發展計劃,進行產業轉型,驅動力量包括日益提升的環境保護意識、嚴格的市場法規以及追求成本效益,因此企業必須把環保永續納入營運過程中,從供應鏈管理到產品開發無一不可避免。 TCA指出,InnoVEX 2024 科技新創雲集,本屆展覽透過「AI」、「ESG綠色科技」、「智慧移動」、「半導體應用」等四大主題展出內容,吸引許多符合主題之廠商參加。InnoVEX 2024共有23個國際辦事處、加速器、政府單位等主題館,將展出旗下熱門技術團隊與新創廠商。 由國立台灣大學光電所孫啟光教授實驗室之衍生新創團隊介觀生醫,致力於發展各項先進之超快雷射與極限光電工程技術,並應用於解決多項長期懸而未決之科學難題;更進而在工程上以影像之方式呈現,以提供目前臨床醫學、神經科學應用等所急需之奈米顯微術工具。
Read More由國科會指導、國研院科政中心執行的「創新創業激勵計畫(From IP to IPO Program)」,透過為期6個月的培訓機制,協助學研擴散創新技術之影響力。 「創新創業激勵計畫」112年第二梯次決選暨頒獎典禮,今(1)日下午在臺灣科技新創基地(TTA)舉辦。由《台大介觀生醫團隊》、《成大基因體醫學中心》、《TPDH》等3組團隊榮獲「創業傑出獎」,並獲得企業贊助的100萬元創業基金,這不但是高技術認證之創業榮譽,更是新創學研團隊進入市場的重要基石。 該梯次學研團隊展現優秀的創新研發能力,並帶著熱忱進行各種研發,決心以科研技術來解決市場痛點,積極勇敢邁出創業第一步。第一階段篩選出40組優秀的學研團隊,在歷經6個月的培訓機制,共7組最具潛力的新創團隊進入決選,並由評審團針對市場趨勢、技術含量及創業決心等進行綜合評估,最終選出3組「創業傑出獎」得主。 國研院科政中心自2013年開始執行「創新創業激勵計畫」,推動至今已超過10年,積極發掘培育具競爭力的新創團隊與青年,深耕各領域的專業師資,並協助鏈結科學園區及國內外業師。為了將學研新創點子順利推向市場,於培訓期間提供早期商業化最重要的三大基礎定位:專利佈局、財務評估與獲利模式精準化等輔導,學研團隊亦於2次商業培訓營與5堂實務課程中融會貫通商化邏輯。 科政中心同時也提供平台線上媒合,以及全年無休輔導專線,致力成為學研團隊發展創新技術與創業第一哩路的最佳夥伴。本梯次歷經專業培訓的新創新星,亦於決選暨頒獎典禮上呈現技術實力與展示培訓成果。 「創新創業激勵計畫」推動至今共培育超過838組新創團隊,成立了403家公司,更帶動民間投入超過82.8億元的創業資金,有效鏈結早期學研新創與民間產業。國科會期許學研團隊的各式創新技術能促成臺灣產業良性循環並活絡國內市場,並勉勵團隊從創業初期即能以可規模化的技術進行國際布局,善用前瞻科學及跨域資源來解決全球性的問題,向全球展現臺灣新創的科技實力。
Read MoreKleopas A. Kleopa and Daniela Menichela- SPC co-Chairs Content Disclaimer: The suggestions listed below are that of the PNS Scientific Program Committee Co-Chairs & do not represent the opinions of the PNS Board, nor the Society as a whole. 1. Novel technologies and ideas have emerged to understand pathomechanisms at single ...
Read MoreTumors of the brain and central nervous system can be fatal, and surgery is often required for their removal. To avoid disease recurrence, it is necessary to ensure that the tumor is completely removed. “While removing the tumor, a clinician often needs to look for any leftover tumor tissue,” Dr. ...
Read More